In addition, the biological functions of abnormal glycans in AD pathology have been reported in some cases; for example, it is known that inhibition of BACE1 glycosylation reduces the cleavage of the amyloid β precursor protein (APP) 21–23. The gene discussed is BACE1; the disease is Alzheimer disease.